# Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT03724747** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 63 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** BAY2315497 Injection
- **DRUG:** Darolutamide(BAY1841788)

## Key facts

- **NCT ID:** NCT03724747
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-18
- **Primary completion:** 2022-08-25
- **Final completion:** 2024-10-31
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03724747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03724747, "Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03724747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*